155 related articles for article (PubMed ID: 12206749)
41. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
42. Solitary pulmonary nodules: accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data.
Keith CJ; Miles KA; Griffiths MR; Wong D; Pitman AG; Hicks RJ
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1016-23. PubMed ID: 12173015
[TBL] [Abstract][Full Text] [Related]
43. Positron emission tomography scanning is coming to a hospital near you soon!
Bashir H; Shabo G; Nunan TO
Clin Med (Lond); 2008 Apr; 8(2):134-9. PubMed ID: 18478853
[TBL] [Abstract][Full Text] [Related]
44. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
[TBL] [Abstract][Full Text] [Related]
45. Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer.
Madsen PH; Holdgaard PC; Christensen JB; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2084-97. PubMed ID: 27164899
[TBL] [Abstract][Full Text] [Related]
46. Positron emission imaging of head and neck cancer, including thyroid carcinoma.
Schöder H; Yeung HW
Semin Nucl Med; 2004 Jul; 34(3):180-97. PubMed ID: 15202100
[TBL] [Abstract][Full Text] [Related]
47. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
[TBL] [Abstract][Full Text] [Related]
49. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
51. Assessment of Fluorodeoxyglucose F18-Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules.
Maiga AW; Deppen SA; Mercaldo SF; Blume JD; Montgomery C; Vaszar LT; Williamson C; Isbell JM; Rickman OB; Pinkerman R; Lambright ES; Nesbitt JC; Grogan EL
JAMA Surg; 2018 Apr; 153(4):329-334. PubMed ID: 29117314
[TBL] [Abstract][Full Text] [Related]
52. The applications of PET in clinical oncology.
Strauss LG; Conti PS
J Nucl Med; 1991 Apr; 32(4):623-48; discussion 649-50. PubMed ID: 2013803
[TBL] [Abstract][Full Text] [Related]
53. Whole-body FDG-PET imaging in the management of patients with cancer.
Hustinx R; Bénard F; Alavi A
Semin Nucl Med; 2002 Jan; 32(1):35-46. PubMed ID: 11839068
[TBL] [Abstract][Full Text] [Related]
54. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography.
Klose T; Leidl R; Buchmann I; Brambs HJ; Reske SN
Eur J Nucl Med; 2000 Oct; 27(10):1457-64. PubMed ID: 11083533
[TBL] [Abstract][Full Text] [Related]
55. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer.
Yoo J; Henderson S; Walker-Dilks C
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):e33-66. PubMed ID: 23021712
[TBL] [Abstract][Full Text] [Related]
56. [18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer].
Dietlein M; Weber W; Schwaiger M; Schicha H
Nuklearmedizin; 2003 Aug; 42(4):145-56. PubMed ID: 12937693
[TBL] [Abstract][Full Text] [Related]
57. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
Pai M; Park CH; Suh JH; Koh JH
Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001
[TBL] [Abstract][Full Text] [Related]
58. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules.
Cao JQ; Rodrigues GB; Louie AV; Zaric GS
Clin Lung Cancer; 2012 May; 13(3):161-70. PubMed ID: 22133290
[TBL] [Abstract][Full Text] [Related]
59. [The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology].
Granov AM; Tiushin LA; Tlostanova MS; Kostenikov NA; Ryzhkova DV; Savello VE; Stanzhevskiĭ AA
Vopr Onkol; 2003; 49(5):563-73. PubMed ID: 14682126
[TBL] [Abstract][Full Text] [Related]
60. PET/CT in oncology: a major technology for cancer care.
Ell PJ
Chang Gung Med J; 2005 May; 28(5):274-83. PubMed ID: 16086542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
